+61 7 3176 4400
Level 1, B2 2 Burke St Woolloongabba Qld 4102 Australia
This report examines an important quality indicator looking at treatment towards end of life. It focuses on intravenous systemic therapy within 14 and 30 days of death in breast, colon, rectal, melanoma, prostate and non-small cell lung cancer.
Although systemic therapy holds immense promise for clinicians and patients alike, it can change from being life-saving to life-limiting in the later stages of the disease. Therefore, a vital safety and quality indicator for cancer teams to monitor.